Used in the treatment of moderate to severe plaque psoriasis, this antibody targets the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their pro-inflammatory signaling. By blocking these cytokines, it helps reduce the immune-driven inflammation responsible for the overproduction of skin cells and associated symptoms in psoriasis. It is also being investigated for other autoimmune conditions such as psoriatic arthritis and inflammatory bowel disease, where IL-12 and IL-23 pathways play a key role. Administered via subcutaneous injection, it offers a targeted therapy option for patients who do not respond adequately to conventional treatments.